| Literature DB >> 26758507 |
W M C Koenraadt1, N Grewal2,3, O Y Gaidoukevitch3, M C DeRuiter3, A C Gittenberger-de Groot1,3, M M Bartelings3, E R Holman1, R J M Klautz2, M J Schalij1, M R M Jongbloed4,5.
Abstract
BACKGROUND: The clinical course of bicuspid aortic valves (BAVs) is variable. Data on predictors of aortopathy and valvular dysfunction mainly focus on valve morphology. AIM: To determine whether the presence and extent of the raphe (fusion site of valve leaflets) is associated with the degree of aortopathy and valvular dysfunction in patients with isolated BAV and associated aortic coarctation (CoA).Entities:
Keywords: Aortic diseases; Echocardiography; Heart defects, Congenital; Valvular heart disease
Year: 2016 PMID: 26758507 PMCID: PMC4722007 DOI: 10.1007/s12471-015-0784-4
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380
Fig. 1Schematic overview of bicuspid aortic valve (BAV) morphologies. The drawings are oriented in an echocardiographic view of the aortic valve. Upper panel: The three major valve morphologies observed in BAV patients are described as three different types based on the valve leaflet orientation: type 1,2 and 3. The extent of the raphe is indicated as analysed in this study (incomplete or complete). Lower panel: Strictly bicuspid valves (without a raphe) are defined as a subgroup B. Modified after Schaefer et al. [9]
Fig. 2Representative examples of different bicuspid aortic valve (BAV) types as seen from the short-axis parasternal view on echocardiography. The yellow arrow indicates the raphe. The orange star indicates the typical fish mouth opening of the valve. a Type 1A in open position. b Type 1A with complete raphe in closed position. c Type 1A with incomplete raphe in closed position. d Type 1B in open position. e Type 1B in closed position. f Type 2A in open position. g Type 2A with complete raphe in closed position. h Type 2A with incomplete raphe in closed position. i Type 2B in open position. j Type 2B in closed position
Patient characteristics
| Variable |
|
|---|---|
| Gender | |
| Male | 179 (70.2) |
| Female | 76 (29.8) |
| Bicuspid aortic valve morphology | |
| Type 1A | 151 (59.2) |
| Type 2A | 37 (14.5) |
| Type 3A | 1 (0.4) |
| Strictly bicuspid (type B) Type 1B Type 2B | 66 (25.9) 42 (63.6) 24 (36.4) |
| Extent of the raphe | |
| Complete | 111 (43.5) |
| Incomplete | 78 (30.6) |
| Valve surgery | 66 (25.9) |
| Mitral valve replacement | 1 (0.39) |
| Mitral valve repair | 2 (0.78) |
| Aortic valve replacement | 50 (19.6) |
| Aortic valve repair | 10 (3.9) |
| Bentall | 22 (8.6) |
| Tricuspid valve repair | 1 (0.39) |
| Pulmonary valve replacement | 1 (0.39) |
| Congenital defects | 51 (20.0) |
| Aortic coarctation | 39 (15.3) |
| Atrial septal defect | 1 (0.39) |
| Ventricular septal defect | 11 (4.3) |
| Marfan | 2 (0.78) |
| Common truncus | 1 (0.39) |
| Patent ductus arteriosus | 5 (2.0) |
| Valvular dysfunction | 189 (74.1) |
| Aortic valve stenosis | 120 (47.1) |
| Aortic valve regurgitation | 120 (47.1) |
| Mitral valve regurgitation | 16 (6.3) |
| Tricuspid valve regurgitation | 8 (3.1) |
| Pulmonary valve stenosis | 1 (0.39) |
| Pulmonary valve regurgitation | 1 (0.39) |
| Medication | 140 (54.9) |
| ACE inhibitors | 91 (35.7) |
| Statins | 61 (23.9) |
| Carbasalate calcium | 45 (17.6) |
| Oral anticoagulants | 43 (16.9) |
| Antiarrhythmic drugs | 33 (12.9) |
| Risk factors | 117 (45.9) |
| Hypertension | 65 (25.5) |
| Smoking | 54 (21.2) |
| Diabetes | 11 (4.3) |
| Cerebrovascular accident | 14 (5.5) |
| Hypercholesterolaemia | 33 (12.9) |
| Peripheral arterial disease | 7 (2.7) |
Patient characteristics of different BAV subgroups
| Total | Type 1A | Type 2A | Type 3A | Type B |
| |
|---|---|---|---|---|---|---|
| Gender (male) | 179 (70 %) | 110 (73 %) | 23 (62 %) | 0 (0 %) | 46 (70 %) | 0.260 |
| Age (years) | 48 ± 15 | 49 ± 14 | 46 ± 17 | 42 ± 25 | 47 ± 15 | 0.515 |
| Risk factors | ||||||
| Diabetes | 11 (4 %) | 8 (5 %) | 2 (5 %) | 0 (0 %) | 1 (2 %) | 0.609 |
| Hypertension | 65 (26 %) | 44 (29 %) | 8 (22 %) | 0 (0 %) | 13 (20 %) | 0.414 |
| Hypercholesterolaemia | 33 (13 %) | 23 (15 %) | 3 (8 %) | 0 (0 %) | 7 (11 %) | 0.585 |
| Smoking | 51 (20 %) | 31 (21 %) | 8 (22 %) | 0 (0 %) | 12 (18 %) | 0.925 |
| Medication | ||||||
| Carbasalate calcium | 45 (18 %) | 19 (13 %) | 8 (22 %) | 1 (100 %) | 17 (26 %) | 0.013 |
| Statins | 59 (23 %) | 31 (21 %) | 9 (24 %) | 1 (100 %) | 18 (27 %) | 0.207 |
| ACE inhibitor | 89 (35 %) | 59 (39 %) | 12 (32 %) | 0 (0 %) | 18 (28 %) | 0.352 |
| Oral anticoagulants | 42 (17 %) | 28 (19 %) | 6 (16 %) | 0 (0 %) | 0 (0 %) | 0.068 |
Fig. 3Schematic overview of the distribution of valve morphologies in the study population
Valve morphology as related to dysfunction
| Valve dysfunction | Complete raphe | Incomplete raphe |
|
|---|---|---|---|
| Valve dysfunction ( | 92 (82.9 %) | 52 (66.7 %) | 0.01 |
| Aortic regurgitation ( | 63 (56.8 %) | 33 (42.3 %) | 0.05 |
| Aortic stenosis ( | 55 (49.5 %) | 34 (43.6 %) | NS |
Valve morphology as related to aortic diameter; type 1A versus type 2A
| Aortic diameter | Type 1A | Type 2A |
|
|---|---|---|---|
| Sinus (mm) | 37.29 ± 5.88 | 33.89 ± 4.84 | 0.001 |
| Ascendens (mm) | 37.34 ± 6.75 | 36.33 ± 7.03 | NS |
| Arch (mm) | 29.30 ± 5.45 | 30.94 ± 4.70 | NS |
Valve morphology as related to aortic diameter in all types BAV with complete raphe versus all types BAV with incomplete raphe
| Aortic diameter | Complete raphe | Incomplete raphe |
|
|---|---|---|---|
| Sinus (mm) | 36.91 ± 5.82 | 36.13 ± 5.81 | NS |
| Ascendens (mm) | 38.02 ± 6.53 | 35.91 ± 7.00 | 0.041 |
| Arch (mm) | 30.07 ± 5.16 | 29.21 ± 5.66 | NS |
Characteristics of patients with type 1A bicuspid aortic valves (BAVs) with coarctation of the aorta (CoA) versus without CoA
| Variable | CoA | No CoA |
|
|---|---|---|---|
| Type 1A BAV, | 22 (56.4 %) | 129 (59.7 %) | NS |
| Raphe | 0.003 | ||
| Incomplete, | 16 (72.7 %) | 50 (38.8 %) | |
| Complete, | 6 (27.3 %) | 79 (61.2 %) | |
| Ascendens (mm) | 33.3 ± 6.06 | 37.8 ± 6.78 | < 0.001 |
| Arch (mm) | 25.5 ± 4.77 | 30.2 ± 4.98 | < 0.001 |
| Valve regurgitation | 3 (13.6 %) | 72 (55.8 %) | < 0.001 |
| Valve stenosis | 10 (45.5 %) | 56 (43.4 % | NS |